scholarly journals Similar outcomes with first-line observation versus metastasectomy for bone giant cell tumor lung metastases

2020 ◽  
Author(s):  
Shinji Tsukamoto ◽  
Giovanni Ciani ◽  
Andreas F. Mavrogenis ◽  
Cristina Ferrari ◽  
Manabu Akahane ◽  
...  
Keyword(s):  
Disease Progression ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Lung Metastases ◽  
Progression Free Survival ◽  
Cell Tumor ◽  
First Line ◽  
Free Survival ◽  
Number Of Patients

Abstract Background: The outcome of lung metastases in patients with giant cell tumor of bone (GCTB) varies from spontaneous regression to uncontrolled growth. To investigate whether observation is an appropriate first-line management for patients with lung metastases from GCTB, we compared the outcomes of patients initially treated with observation with those treated with metastasectomy.Methods: We retrospectively reviewed the data of 29 patients with lung metastases from histologically confirmed GCTB. The median follow-up period was 114 months. We evaluated progression-free survival, which was defined as the time from the date of occurrence of lung metastases to the date of disease progression in the observation or incomplete metastasectomy group, disease recurrence in the complete metastasectomy group, or the last follow-up.Results: Disease progression or recurrence occurred in 14 patients (48.3%). Progression-free survival did not vary significantly between the observation and metastasectomy groups (p=0.373). The total number of metastasectomies was significantly higher in the initial metastasectomy group than in the observation group (p=0.017).Conclusions: The number of patients included in this study is small, however the data suggests that observation can be used safely as first-line management for patients with lung metastases from GCTB with an outcome similar to that of metastasectomy. It is necessary to confirm our result in multi-institutional study with sufficient number of patients.

scholarly journals Similar outcomes with first-line observation versus metastasectomy for bone giant cell tumor lung metastases

2020 ◽  
Author(s):  
Shinji Tsukamoto ◽  
Giovanni Ciani ◽  
Andreas F. Mavrogenis ◽  
Cristina Ferrari ◽  
Manabu Akahane ◽  
...  
Keyword(s):  
Disease Progression ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Lung Metastases ◽  
Progression Free Survival ◽  
Cell Tumor ◽  
First Line ◽  
Free Survival ◽  
Line Management

Abstract Background: The outcome of lung metastases in patients with giant cell tumor of bone (GCTB) varies from spontaneous regression to uncontrolled growth. To investigate whether observation is an appropriate first-line management for patients with lung metastases from GCTB, we compared the outcomes of patients initially treated with observation with those treated with metastasectomy.Methods: We retrospectively reviewed the data of 29 patients with lung metastases from histologically confirmed GCTB. The median follow-up period was 114 months. We evaluated progression-free survival, which was defined as the time from the date of occurrence of lung metastases to the date of disease progression in the observation or incomplete metastasectomy group, disease recurrence in the complete metastasectomy group, or the last follow-up.Results: Disease progression or recurrence occurred in 14 patients (48.3%). Progression-free survival did not vary significantly between the observation and metastasectomy groups (p=0.373). The number of metastasectomies was significantly higher in the initial metastasectomy group than in the observation group (p=0.017).Conclusions: Observation can be used safely as first-line management for patients with lung metastases from GCTB with an outcome similar to that of metastasectomy.

scholarly journals Outcome of lung metastases due to bone giant cell tumor initially managed with observation

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Shinji Tsukamoto ◽  
Giovanni Ciani ◽  
Andreas F. Mavrogenis ◽  
Cristina Ferrari ◽  
Manabu Akahane ◽  
...  
Keyword(s):  
Disease Progression ◽  
Giant Cell Tumor ◽  
Spontaneous Regression ◽  
Lung Metastases ◽  
Cell Tumor ◽  
Lung Nodules ◽  
First Line ◽  
Denosumab Treatment ◽  
Median Interval

Abstract Background The outcomes of patients with lung metastases from giant cell tumor of bone (GCTB) vary from spontaneous regression to uncontrolled growth. To investigate whether observation is an appropriate first-line management approach for patients with lung metastases from GCTB, we evaluated the outcomes of patients who were initially managed by observation. Methods We retrospectively reviewed the data of 22 patients with lung metastases from histologically confirmed GCTB who received observation as a first-line treatment approach. The median follow-up period was 116 months. Results Disease progression occurred in 12 patients (54.5%). The median interval between the discovery of lung metastases and progression was 8 months. Eight patients underwent metastasectomy following initial observation. The median interval between the discovery of lung metastases and treatment by metastasectomy was 13.5 months. None of the patients experienced spontaneous regression. Of the 22 patients, 36.4% needed a metastasectomy, and 9.1% required denosumab treatment during the course of the follow-up period. Disease progression occurred in 45.5% of the 11 patients with lung nodules ≤ 5 mm, while all five of the patients with lung nodules > 5 mm experienced disease progression. Progression-free survival was significantly worse in the group with lung nodules > 5 mm compared to the group with lung nodules ≤ 5 mm (p = 0.022). Conclusions Observation is a safe first-line method of managing patients with lung metastases from GCTB. According to radiological imaging, approximately half of the patients progressed, and approximately half required a metastasectomy or denosumab treatment. However, patients with lung nodules > 5 mm should receive careful observation because of the high rate of disease progression in this group.

In situ cell cycle analysis in giant cell tumor of bone reveals patients with elevated risk of reduced progression-free survival

Bone ◽  
2019 ◽  
Vol 127 ◽  
pp. 188-198 ◽  
Author(s):  
Mate E. Maros ◽  
Sven Schnaidt ◽  
Peter Balla ◽  
Zoltan Kelemen ◽  
Zoltan Sapi ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Progression Free Survival ◽  
Elevated Risk ◽  
Cell Tumor ◽  
Cell Cycle Analysis ◽  
Free Survival

Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4072-4072 ◽  
Author(s):  
A. Kretzschmar ◽  
E. Van Cutsem ◽  
M. Michael ◽  
F. Rivera ◽  
S. Berry ◽  
...  
Keyword(s):  
Disease Progression ◽  
Progression Free Survival ◽  
Phase Iii ◽  
First Line ◽  
Free Survival ◽  
Similar Patient ◽  
Secondary Endpoints ◽  
Large Phase ◽  
Ecog Ps

4072 Background: In a phase III pivotal trial in patients (pts) with metastatic colorectal cancer (mCRC), BEV (BEV, Avastin®) increased overall survival (OS) by 30% when added to first-line IFL chemotherapy (CT). Recently, a second trial reported a significant improvement in progression free survival (PFS) when BEV was added to FOLFOX/XELOX in a similar patient population. Although, First BEAT was opened to evaluate the safety profile of BEV in a broader pt population using a variety of CT regimens, efficacy endpoints were investigated. Methods: First BEAT enrolled 1,927 mCRC patients in 41 countries between June 2004 and February 2006. Eligible pts were treated with first-line CT (physician’s choice) in combination with BEV (5mg/kg q2w [5-FU-based CT] or 7.5mg/kg q3w [capecitabine [cap, Xeloda®]-based CT]) until disease progression. Secondary endpoints included OS, time to progression (TTP) and PFS. Disease progression was assessed by investigators. Results: By Nov 15th, 2006, 1,914/1,927 pts had data available for analysis (male 58%; median age 59 years, 33% =65 years; ECOG PS 0/1 65%/34%). Median follow-up was 15 months; 60-day mortality was 2.5%. Patients receiving 5-FU/cap CT appeared to have poorer prognosis with respect to age =65 years (41%), ECOG PS 0/1 (58%/42%) and 60-day mortality rate (6.6%), compared with those receiving doublet CT regimens. The most common first-line CT regimens used with BEV were FOLFOX (28%), FOLFIRI (26%), XELOX (18%) and 5-FU or cap CT (16%). Median PFS was 10.4 (95% CI: 10.1–10.9 months, based on 882 events), 10.5 (9.7 - 11.6) in FOLFOX, 10.3 (9.7 - 10.7) in XELOX, 11.1 (10.2–12.0) in FOLFIRI and 9.1 (8.1–10.3) in pts receiving 5-FU or cap CT, respectively. TTP was 10.8 (95% CI: 10.4–11.3 months, based on 805 events). Updated analyses will be presented. Conclusions: In this ongoing, large community-based study, the preliminary efficacy of first line BEV in mCRC pts receiving a variety of CT regimens appears consistent with that observed in large phase III randomised trials. [Table: see text]

scholarly journals Giant cell tumor of the capitate: an unusual case with 10 years follow-up

SICOT-J ◽  
2015 ◽  
Vol 1 ◽  
pp. 18 ◽  
Author(s):  
Serda Duman ◽  
Hakan Sofu ◽  
Yalkin Camurcu ◽  
Sarper Gursu ◽  
Ramadan Oke
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Unusual Case ◽  
Cell Tumor

scholarly journals Giant Cell Tumor of Bone: Oncological and Functional Results of Long-term Follow-up

1998 ◽  
Vol 28 (5) ◽  
pp. 323-328 ◽  
Author(s):  
Y. Oda ◽  
H. Miura ◽  
M. Tsuneyoshi ◽  
Y. Iwamoto
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Functional Results ◽  
Cell Tumor ◽  
Long Term Follow Up

Bilateral Lung Metastases From a Phalangeal Giant Cell Tumor of Bone

2020 ◽  
pp. 109352662096435
Author(s):  
Annie Orr ◽  
Huifei Liu ◽  
Rachel Mariani ◽  
Jennifer H Aldrink ◽  
Bhuvana A Setty ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Residual Disease ◽  
Lung Metastases ◽  
Transcriptome Profiling ◽  
Cell Tumor ◽  
Wide Resection ◽  
Genetic Changes ◽  
Metastatic Lung ◽  
Bilateral Lung

We describe a rare pediatric case of a phalangeal giant cell tumor of bone with extensive bilateral lung metastases following curettage, wide resection, and amputation. Concurrent peripheral blood eosinophilia and pleural effusion with marked eosinophilia (47%) were present. To discover genetic changes driving tumor metastasis, genomic and transcriptome profiling of the metastatic lung mass as well as germline analysis were performed. Whole exome sequencing detected a histone H3F3A p.G35V missense mutation in tumor cells. RNA sequencing revealed overexpression of receptor activator of nuclear factor kappa-B ligand (RANKL). The patient is alive with no residual disease and uncompromised respiratory function 29 months after amputation of primary tumor and 19 months after surgical resection of his metastatic lung disease.

scholarly journals A Case Report of Giant Cell Tumor of Proximal Fibula in Children

2020 ◽  
Vol 4 (1) ◽  
pp. 64-67
Author(s):  
Sushil Adhikari ◽  
Arun Sigdel ◽  
Rajesh Kumar Sah ◽  
Luna Devkota
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Long Bone ◽  
Lytic Lesion ◽  
Radiographic Appearance ◽  
X Ray ◽  
Proximal Fibula ◽  
Aggressive Tumor

Giant cell tumour (GCT) is histopathologically benign tumor of long bone particularly in distal femur and the proximal tibia. It commonly occurs in adults of age 20-40 years but rare in children. GCT is considered to be locally aggressive tumor and tendency of recurrence is higher even after surgery. The clinical features are nonspecific, the principle symptoms are pain, swelling and limiting adjacent joint movements. Diagnosis is based on the radiographic appearance and histopathological findings .In our case X-ray showed ill defined lytic lesion on proximal fibula with cortical thinning and MRI finding revealed expansile lyticlesion in meta-epiphysis of right fibula 16×16×28mm adjacent to growth plate with fluid level. The sclerotic rim appears hypo intense on T1 & hyper intense on T2. Core needle biopsy showed giant cell tumor on proximal fibula. Considering the risk of recurrence wide local excision was done. Management of GCT of proximal fibula in young patient is critical for preventing recurrence and enhancing functional outcomes by saving adjacent anatomical structure. No evidence of local recurrence and metastasis was found in 24 months of follow up.

GIANT CELL TUMOR OF TENDON SHEATH MIMICKING PYOGENIC GRANULOMA IN THE INDEX FINGER PULP: A CASE REPORT

Hand Surgery ◽  
2012 ◽  
Vol 17 (01) ◽  
pp. 125-127
Author(s):  
J. Terrence Jose Jerome ◽  
Kumar Venkatesan ◽  
Amarnath G ◽  
Usha Rani ◽  
Rohini Sridhar
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Clinical Presentation ◽  
Index Finger ◽  
Pyogenic Granuloma ◽  
Tendon Sheath ◽  
Cell Tumor ◽  
Complete Excision ◽  
Study Base

We report a 75-year-old man who presented with a painless friable mass in the index finger pulp mimicking pyogenic granuloma. Complete excision of the mass was done. The radiological and the histopathological findings suggested giant cell tumor of the tendon sheath. The patient had no recurrence at the end of a two-year follow-up. This unusual clinical presentation of the giant cell tumor of the tendon sheath was our study base and adds up to its variant presentation in the literature.

Sign in / Sign up

Export Citation Format

Share Document